Last reviewed · How we verify

NCT00745771

Multiple Dose, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness From Exercise

Completed Phase 2 Last updated 19 March 2009
What this trial tests

Phase 2 trial testing Diractin in Muscle Soreness in 168 participants. Completed in 1 November 2008.

Timeline
1 October 2007
Primary endpoint
1 February 2008
1 November 2008

Quick facts

Lead sponsorIDEA AG
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Primary purposetreatment
Enrollment168
Start date1 October 2007
Primary completion1 February 2008
Estimated completion1 November 2008
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

IDEA AG — full company profile →

Who can join

Adults 18 to 55, any sex, with Muscle Soreness. Healthy volunteers can join.

Sponsor's own description

Multiple-dose, double-blind, double-dummy, parallel, randomized, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for muscle soreness from exercise.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Muscle Soreness

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00745771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing